Tests music therapy for irritability in early Huntington's disease
Tests music therapy with usual care in adults with early Huntington's disease.
Plain-language title generated from the registry record
Registry title: Study to Evaluate Music Therapy on Irritability and Impulsivity in Patients With Huntington's Disease (MUSIC-HD)
Key facts
- Where
- Poitiers, FranceSee the site
Where in France
- CHU Poitiers / CICPoitiers, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Poitiers University Hospital
- Trial code
- NCT06414967
- Record updated
- 29 December 2025
- Original description
The study is an open-label clinical trial evaluating whether music therapy combined with conventional management reduces irritability and impulsivity in 15 patients with early-stage Huntington's disease. This pilot study aims to show the interest of alternative non-pharmacological measures such as a digital music therapy tool, adapted to an audience of Huntington's patients, to help manage the psychobehavioral symptoms frequently observed in this affection, and to avoid breakdowns due to caregiver exhaustion.Read full original descriptionShow less
Pilot Study Evaluating the Benefits of Music Therapy Combined With Conventional Treatment on Irritability and Impulsivity in Patients With Huntington's Disease (MUSIC-HD)
The study is an open-label clinical trial evaluating whether music therapy combined with conventional management reduces irritability and impulsivity in 15 patients with early-stage Huntington's disease. This pilot study aims to show the interest of alternative non-pharmacological measures such as a digital music therapy tool, adapted to an audience of Huntington's patients, to help manage the psychobehavioral symptoms frequently observed in this affection, and to avoid breakdowns due to caregiver exhaustion.
Inclusion: Age >= 18 years; Huntington disease genetically confirmed by the presence of at least 35 repeats of the CAG triplet in exon 1 of the HTT gene; UHDRS (Unified Huntington's disease Rating Scale) score <= 5 with a diagnostic confidence score =4; Absence of significant cognitive impairment MoCA >=24; Stable drug therapy in the 28 days prior inclusion and during the study; Without legal tutors or subordination; Affiliated to a health insurance system as required by the French law on biomedical research; Written informed consent for participation in the study.
Exclusion: Significant hearing impairment; Inability to give free and informed consent for study participation; Participating to another study the day of enrollement; Persons benefiting from enhanced protection, i.e.persons deprived of their liberty by a judicial or administrative decision, adults under legal and finally patients in a vital emergency situation.